Investigate / CNC
Understand CENTENE CORP
Can Centene align premiums with medical costs and acuity as Medicaid and Marketplace policy keeps changing?
Snapshot reviewed 2026-10-02. Source published 2026-07-28. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Ownership-page coverage is not available for this company. That does not mean no tracked investor owns it.
Your research workspace / CNC
Ask better questions. Keep the evidence.
Explore the available sources for CENTENE CORP, then keep what deserves another look.
01 Investor activity
Ownership coverage is unavailable—not zero owners.
02 Business evidence
Reported evidence
What does the company do?
Centene offers managed-care products to underserved populations, including Medicaid, Medicare, prescription-drug-plan and Health Insurance Marketplace members.
Latticework interpretation
What could support the case?
If state Medicaid premium rates match population acuity and recent medical-cost trends, they could better align premiums with the costs Centene faces.
Latticework interpretation
What could break the case?
Because health plan margins are narrow, relatively small changes in the health benefits ratio could materially change results if actual medical expenses exceed estimates.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
Centene offers managed-care products to underserved populations, including Medicaid, Medicare, prescription-drug-plan and Health Insurance Marketplace members.
Source: Annual filing · business description ↗2. What the reported results show
Latest source: 10-Q, reporting period ended 2026-06-30. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue from customer contracts ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. Excludes assessed tax; this concept may exclude other company revenue. | $44,375m | $42,467m |
| Operating income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $1,198m | −$458m |
| Net income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $1,091m | −$253m |
| Operating cash flow ↗Six months (year to date): 2026-01-01–2026-06-30; prior 2025-01-01–2025-06-30Both values reported in the current filing. Operating cash flow is not free cash flow or a standalone solvency assessment; inspect the full statement. | $7,956m | $3,295m |
Comparison caveat: Revenue shown is premium and service revenue, excluding premium tax. Earnings also reflect risk-adjustment changes, and cash includes payment timing; neither comparison alone proves recurring improvement.
10-Q · latest checked financial statements and discussion ↗3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If state Medicaid premium rates match population acuity and recent medical-cost trends, they could better align premiums with the costs Centene faces.
Supporting filing ↗The strongest caution
Because health plan margins are narrow, relatively small changes in the health benefits ratio could materially change results if actual medical expenses exceed estimates.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
Do Medicaid rate adjustments keep pace with acuity?
Starting evidence: Rate setting relies on historical data, so a delay between paying claims and receiving rate adjustments could matter when medical cost trends rise quickly.
Investigate next: Review state rate-update timing, any retroactive adjustments, and management commentary on rate-to-acuity alignment by state.
Read the supporting filing ↗How might OBBBA changes affect Medicaid Expansion membership mix?
Starting evidence: Work requirements, more frequent eligibility checks and co-pays could increase Medicaid Expansion morbidity, depending on state implementation plans.
Investigate next: Investigate state implementation timelines, expected membership shifts, and how management plans to price for a higher-acuity population.
Read the supporting filing ↗How exposed is Marketplace to risk adjustment and subsidy changes?
Starting evidence: Independent actuarial data suggested higher implied Marketplace morbidity than anticipated, reducing expected net risk adjustment revenue.
Investigate next: Examine risk adjustment methodology, how morbidity estimates are updated, and the effect of expired enhanced premium tax credits on membership and pricing.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.